330 articles in this topic
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
A large global Phase III trial evaluated the efficacy, safety, and immunogenicity of CanSino's adenovirus-vectored COVID-19 vaccine across 44,247 adults.
A rigorous Cochrane protocol sets the stage to evaluate whether vitrectomy surgery outperforms drug therapy alone for non-infectious uveitis.
The FDA has approved the first treatment specifically targeting chronic hepatitis delta, the most severe form of viral hepatitis.
Researchers uncover how the STING immune pathway triggers mitochondrial fragmentation and DNA release, fueling deadly lung inflammation in sepsis.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
A major Cochrane network meta-analysis protocol aims to compare and rank interventions for preeclampsia prevention before 17 weeks gestation.
A published correction updates the April 2026 Aging Cell paper identifying a senescence-driven, immunomodulatory subtype of endometriosis.
GSK's HRV vaccine faces its biggest test yet — can it prevent severe rotavirus gastroenteritis without raising intussusception risk?
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
A 65-year-old man with cavin-4 IgG rippling muscle disease achieved full remission after rituximab — offering hope for this rare condition.
A Phase 2 trial testing maraviroc and favipiravir for severe COVID-19 was terminated before completion, leaving efficacy data incomplete.
